Purpose of this invention makes the improvement and efficient medicinal effect revelation of directivity to the liver possible, there are times when the medicine composition which contains with the medicine carrier, and the particular carrier and the medicine which contain the new useful galactose derivative and the particular derivative which are the constitution component of the medicine carrier is offered. This invention, the galactose derivative, the particular derivative and contain the cation characteristic lipid the medicine carrier and the particular carrier and the medicine which are displayed with below-mentioned general formula (i) (is desirable, two these chains RNA and two these chains DNA, origo nuclear acid) with it is something regarding the medicine composition which is contained.< Conversion 6 > In formula (i), R1 hydrogen, the carbon count displays alkyl, or 1-(D)- deokishirakuchito -1- iru 1 which is possible to be substituted - 10. R2 carbon count saturation 10 - 30 or displays the unsaturated fatty acid residue.< Selective figure >It is not本発明の目的は、肝臓への指向性の向上及び効率的な薬効発現を可能とする、薬物担体の構成成分である新規有用なガラクトース誘導体、当該誘導体を含有する薬物担体、及び当該担体と医薬とを含有する医薬組成物を提供することにある。本発明は、下記一般式(I)で表されるガラクトース誘導体、当該誘導体とカチオン性脂質とを含有する薬物担体及び当該担体と医薬(好ましくは、二本鎖RNA、二本鎖DNA、オリゴ核酸)とを含有する医薬組成物に関するものである。【化6】式(I)中、R1は水素、置換されていてもよい炭素数1~10のアルキル、又は1-(D)-デオキシラクチト-1-イルを表す。R2は炭素数10~30の飽和又は不飽和の脂肪酸残基を表す。【選択図】なし
